Guobang Pharma Ltd Net Asset Quality Index
Guobang Pharma Ltd net asset quality index. Guobang Pharma Ltd (605507) has a Net Asset Quality Index of 73.8% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥11.38 Billion minus total liabilities of CN¥2.98 Billion yields net assets of CN¥8.40 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Guobang Pharma Ltd (605507) shareholders funds for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Guobang Pharma Ltd (2017–2025)
Net asset quality index of Guobang Pharma Ltd from 2017 to 2025. This chart shows how Guobang Pharma Ltd's Net Asset Quality Index has evolved across 9 annual periods from 2017 to 2025. As of June 2026, the index stands at 73.8%, representing net assets of CN¥8.40 Billion against total assets of CN¥11.38 Billion CNY. Check Guobang Pharma Ltd (605507) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Guobang Pharma Ltd Net Asset Quality Index by Year (2017–2025)
Guobang Pharma Ltd net asset quality index by year from 2017 to 2025. The table below presents the year-by-year Net Asset Quality Index for Guobang Pharma Ltd from 2017 to 2025, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 605507 market cap overview.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 77.9% | CN¥8.56 Billion | CN¥10.98 Billion | CN¥2.43 Billion | ▲ +3.2 pp |
| 2024 | 74.7% | CN¥8.05 Billion | CN¥10.78 Billion | CN¥2.73 Billion | ▲ +2.9 pp |
| 2023 | 71.8% | CN¥7.44 Billion | CN¥10.36 Billion | CN¥2.92 Billion | ▼ -7.3 pp |
| 2022 | 79.1% | CN¥7.15 Billion | CN¥9.04 Billion | CN¥1.89 Billion | ▼ -5.3 pp |
| 2021 | 84.5% | CN¥6.35 Billion | CN¥7.51 Billion | CN¥1.17 Billion | ▲ +25.0 pp |
| 2020 | 59.4% | CN¥3.27 Billion | CN¥5.51 Billion | CN¥2.23 Billion | ▲ +4.5 pp |
| 2019 | 55.0% | CN¥2.62 Billion | CN¥4.76 Billion | CN¥2.14 Billion | ▼ -4.4 pp |
| 2018 | 59.4% | CN¥2.59 Billion | CN¥4.37 Billion | CN¥1.77 Billion | ▲ +4.5 pp |
| 2017 | 54.9% | CN¥2.21 Billion | CN¥4.02 Billion | CN¥1.82 Billion | — |